liver disease
Conditions
Interventions
Experimental group:Adjust the dose of immunosuppressive agent according to Cylex ATP value combined with drug concentration
Control group:Adjust the dose of tacrolimus or cyclosporine according to "Guidelines for Clinical Diagnosis and Treatment of pediatric Liver Transplantation (2015 Edition)''
PKPD group:Tacrolimus intervention
Sponsors
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) The family members of the patients voluntarily signed the informed consent form and were orally informed of the specific test plan; 2) Chinese nationality; 3) The age of children undergoing first liver transplantation is between 5 and 36 months; 4) Weigh 5 kg or more.
Exclusion criteria
Exclusion criteria: 1) Children undergoing retransplantation or multi-organ transplantation; 2) Preoperative severe acute liver failure and emergency liver transplantation were considered excluded; 3) Children undergoing liver transplantation due to liver tumor; 4) ABO-incompatible liver transplantation; 5) The drug combination that affect the activity of CYP3A, such as erythromycin and itraconazole; 6) Children with different immunosuppressive regimens, such as sulai induction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Post-transplant infection; | — |
Secondary
| Measure | Time frame |
|---|---|
| acute rejection;Population Pharmacokinetics; | — |
Countries
China
Contacts
Public ContactXia Qiang
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Outcome results
None listed